Suscribirse

PNEUMOCOCCAL VACCINE - 06/09/11

Doi : 10.1016/S0031-3955(05)70207-8 
Lorry G. Rubin, MD *

Resumen

Streptococcus pneumoniae, or pneumococcus, is an encapsulated gram-positive coccus. Pneumococci are a major cause of common upper respiratory infections and life-threatening, invasive infections in children, adolescents, and adults in the United States and worldwide resulting in much morbidity and mortality. Pneumococci cause an estimated 3000 cases of meningitis, 50,000 cases of bacteremia, and 500,000 cases of pneumonia in the United States each year.12 Cases of bacterial pneumonia and meningitis account for more than 500,000 hospitalizations and more than 40,000 deaths in the United States each year. In the United States, pneumococci are the most common cause of bacterial meningitis in children 1 to 23 months of age54 and pyogenic pneumonia in pediatric patients beyond the neonatal period. The spectrum of invasive infections caused by pneumococci also includes septic arthritis, osteomyelitis, bacteremic cellulitis, primary peritonitis, and occult bacteremia in highly febrile infants and young children, and sepsis that may be rapidly fatal in immunocompromised hosts, such as those with impaired splenic function. S. pneumoniae is the leading cause of the common bacterial upper respiratory tract infections, acute otitis media and sinusitis. Seven million cases of acute otitis media are diagnosed each year in the United States, and 62% of US infants have an episode of otitis media during the first year of life.12

The pneumococcal cell may be enveloped by 1 of at least 90 chemically distinct polysaccharide capsules. Landmark studies performed during the first half of the twentieth century demonstrated that protective immunity was conferred by serum from rabbits injected with heat-killed pneumococci, that the protective activity of the serum is pneumococcal type specific, and that polysaccharide capsular is the major virulence factor and is the target of type-specific immunity (i.e., antibody). These findings led to capsular typing of pneumococcal isolates using antiserum prepared in animals by the Quellung reaction, which is the capsular swelling noted microscopically after incubation of the isolate withtype-specific antiserum. In early studies, killed bacteria and later purified capsular polysaccharides were studied as vaccines. In addition, capsular type-specific horse antiserum was used for the treatment of pneumococcal infection in humans. Thus, by the mid-1900s, researchers had established that capsule serves as a major virulence determinant, allowing the bacterium to resist phagocytosis and killing in the absence of anticapsular antibodies. They had also established that serotype-specific, anticapsular antibodies can be generated by immunization and play a major role in type-specific protection against pneumococcal disease.

El texto completo de este artículo está disponible en PDF.

Esquema


 Address reprint requests to Lorry G. Rubin, MD, Schneider Children's Hospital, 269–01 76th Avenue, New York, NY 11040, e-mail: [email protected]


© 2000  W. B. Saunders Company. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 47 - N° 2

P. 269-285 - avril 2000 Regresar al número
Artículo precedente Artículo precedente
  • Childhood Immunizations 2000. Introduction
  • Larry I. Lutwick, Lorry G. Rubin
| Artículo siguiente Artículo siguiente
  • POLIOVIRUS VACCINES : Progress Toward Global Poliomyelitis Eradication and Changing Routine Immunization Recommendations in the United States
  • Roland W. Sutter, D. Rebecca Prevots, Stephen L. Cochi

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.